Holen Sie sich die Stockscreener-App
5.06
0.20%
-0.01
Handel nachbörslich:
5.06
Schlusskurs vom Vortag:
$5.07
Offen:
$5.05
24-Stunden-Volumen:
3.37M
Relative Volume:
0.96
Marktkapitalisierung:
$959.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-196.48M
KGV:
-4.1619
EPS:
-1.2158
Netto-Cashflow:
$-183.16M
1W Leistung:
-1.36%
1M Leistung:
-3.07%
6M Leistung:
+2.02%
1J Leistung:
+119.05%
1-Tages-Spanne:
$4.80
$5.13
1-Wochen-Bereich:
$4.80
$5.59
52-Wochen-Spanne:
$2.03
$7.18
Annexon Inc Stock (ANNX) Company Profile
Firmenname
Annexon Inc
Sektor
Branche
Telefon
(650) 822-5500
Adresse
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
5.06 | 982.02M | 0 | -196.48M | -183.16M | -1.2158 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-30 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-05-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-09-16 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | BTIG Research | Buy |
| 2021-11-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-09-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-26 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | BofA Securities | Buy |
| 2020-08-18 | Eingeleitet | Cowen | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Annexon Inc Aktie (ANNX) Neueste Nachrichten
Annexon (ANNX): Pipeline Momentum Is Building, but Cash Discipline Still Runs the Story - AlphaStreet
Annexon (ANNX) Q2 2026 Earnings Call Transcript - AOL.com
Annexon, Inc. Stock 12‑Month Price Target Raised to $15.71, Implies 198% Upside - TradingView
Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4) - marketscreener.com
Bank of America Corp DE Has $23.60 Million Stock Holdings in Annexon, Inc. $ANNX - MarketBeat
Annexon Inc (ANNX) Stock News Today - TradingKey
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
At $5.29, Annexon grants new employees options vesting over four years - Stock Titan
Annexon (ANNX) Adds Dual Primary Endpoint in Phase 3 Trial, Refl - GuruFocus
Annexon (ANNX) Earnings Call zu Q2 2026: ARCHER II erweitert, BLA-Einreichung im Zeitplan - TradingKey
Annexon (ANNX) Q2 2026 Earnings Call: ARCHER II Expanded, BLA Filing on Track - TradingKey
Annexon grants new hires options for 287,500 shares at $5.29 each - Bitget
What is HC Wainwright's Estimate for Annexon Q3 Earnings? - MarketBeat
Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II TrialWhat's Changed - Sahm
Annexon (NASDAQ:ANNX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
ANNX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
State Street Corp Boosts Annexon Inc (ANNX) Stake by 42% in June Transaction - GuruFocus
A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $8 to $27 - Moomoo
Insider for ANNX (ANNX) plans sale of 2,000 shares after option exercise - Stock Titan
Annexon (ANNX), What Is Behind Its Latest Update? - Yahoo Finance
ANNX Upgraded by Citizens -- Rating Changed to Market Perform - GuruFocus
Annexon (NASDAQ:ANNX) Upgraded at Citizens Jmp - MarketBeat
BofA Securities Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Citizens upgrades Annexon stock rating on trial endpoint changes - Investing.com
Annexon Announces $55.3 Million Net Loss in Q2 2026 Financial Results - Kalkine Media
Form 8K Annexon Inc For: 12 August By Investing.com - Investing.com Nigeria
Annexon, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Annexon (NASDAQ: ANNX) reports $99.5M H1 2026 loss and secures new $200M debt facility - Stock Titan
Needham Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Annexon Q2 2026 Earnings Call Transcript - MarketBeat
Annexon (NASDAQ:ANNX) Issues Earnings Results, Misses Estimates By $0.05 EPS - MarketBeat
Annexon Releases Q2 2026 Financial Results - AlphaStreet
Investors Purchase High Volume of Call Options on Annexon (NASDAQ:ANNX) - MarketBeat
Annexon (NASDAQ:ANNX) Shares Gap Down on Disappointing Earnings - MarketBeat
Annexon Reports Q2 2026 Financials and Expands Vonaprument Phase 3 Trial in Geographic Atrophy - Kalkine Media
Earnings call transcript: Annexon misses Q2 2026 EPS view as shares fall premarket - Investing.com Nigeria
Transcript : Annexon, Inc., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
Annexon Q2 Earnings Call Highlights - MarketBeat
ANNX: Expanded pivotal trials and strong clinical results drive regulatory and financial momentum - TradingView
Annexon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Annexon Q2 Results: Net loss widens to $55.3M on higher R&D - scanx.trade
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study - Investing News Network
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones - Investing News Network
Annexon shares fall as second-quarter loss exceeds Wall Street forecasts - Yahoo Finance
Annexon adds month 24 endpoint to phase 3 dry AMD trial - Investing.com Nigeria
Annexon Expands Vonaprument Phase 3 Trial With Month 24 Dual Primary Endpoint - marketscreener.com
Why is Annexon stock sliding today? By Investing.com - Investing.com Canada
Annexon shares fall 6% on wider-than-expected quarterly loss By Investing.com - Investing.com South Africa
Annexon (Nasdaq: ANNX) deepens pipeline, adds $200M credit facility and new endpoints - Stock Titan
Annexon Q2 Loss Narrows; Shares Down Pre-Bell - marketscreener.com
Annexon shares fall 6% on wider-than-expected quarterly loss - Investing.com
Finanzdaten der Annexon Inc-Aktie (ANNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):